Cilostazol improves cognitive function in patients with mild cognitive impairment

A retrospective analysis

Akihiko Taguchi, Yu Takata, Masafumi Ihara, Yukiko Kasahara, Masahiro Tsuji, Madoka Nishino, David Stern, Masahiro Okada

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background and purpose: Cerebral ischemia and accumulation of amyloid β (Aβ) are major risk factors for the development of dementia, including vascular dementia and Alzheimer's disease. Cilostazol, an antiplatelet drug, has been shown to improve cerebral circulation and reduce accumulation of Aβ. In this study, the long-term effect of cilostazol on cognitive function was investigated retrospectively. Methods: Medical records at Sumotoitsuki Hospital were surveyed to find all patients treated with cilostazol and evaluated by the Mini-Mental State Examination (MMSE) during at least two visits separated by an interval of more than 6 months. Patients receiving anti-dementia drugs were excluded. Temporal changes in MMSE scores were compared between patients treated with cilostazol (n = 70) and those who ceased administration of this drug (n = 22). The mean follow-up period was 691 days. Results: Decrease in MMSE score was significantly ameliorated by administration of cilostazol. Subgroup analysis revealed that cilostazol significantly improved MMSE score in patients with mild cognitive impairment, though no significant effect was observed in patients with normal cognitive function or dementia. Conclusions: Although there are limitations to such a retrospective study, these results significantly encourage undertaking a prospective cohort study to determine the effect of cilostazol on mild cognitive impairment where no treatments currently exist.

Original languageEnglish (US)
Pages (from-to)164-169
Number of pages6
JournalPsychogeriatrics
Volume13
Issue number3
DOIs
StatePublished - Sep 1 2013

Fingerprint

Cognition
Dementia
Cerebrovascular Circulation
Vascular Dementia
Platelet Aggregation Inhibitors
cilostazol
Cognitive Dysfunction
Brain Ischemia
Vascular Diseases
Amyloid
Pharmaceutical Preparations
Medical Records
Alzheimer Disease
Cohort Studies
Retrospective Studies
Prospective Studies

All Science Journal Classification (ASJC) codes

  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Gerontology
  • Medicine(all)

Cite this

Taguchi, A., Takata, Y., Ihara, M., Kasahara, Y., Tsuji, M., Nishino, M., ... Okada, M. (2013). Cilostazol improves cognitive function in patients with mild cognitive impairment: A retrospective analysis. Psychogeriatrics, 13(3), 164-169. https://doi.org/10.1111/psyg.12021

Cilostazol improves cognitive function in patients with mild cognitive impairment : A retrospective analysis. / Taguchi, Akihiko; Takata, Yu; Ihara, Masafumi; Kasahara, Yukiko; Tsuji, Masahiro; Nishino, Madoka; Stern, David; Okada, Masahiro.

In: Psychogeriatrics, Vol. 13, No. 3, 01.09.2013, p. 164-169.

Research output: Contribution to journalArticle

Taguchi, A, Takata, Y, Ihara, M, Kasahara, Y, Tsuji, M, Nishino, M, Stern, D & Okada, M 2013, 'Cilostazol improves cognitive function in patients with mild cognitive impairment: A retrospective analysis', Psychogeriatrics, vol. 13, no. 3, pp. 164-169. https://doi.org/10.1111/psyg.12021
Taguchi, Akihiko ; Takata, Yu ; Ihara, Masafumi ; Kasahara, Yukiko ; Tsuji, Masahiro ; Nishino, Madoka ; Stern, David ; Okada, Masahiro. / Cilostazol improves cognitive function in patients with mild cognitive impairment : A retrospective analysis. In: Psychogeriatrics. 2013 ; Vol. 13, No. 3. pp. 164-169.
@article{b6f21e0908e646acac4577bbe7586f6a,
title = "Cilostazol improves cognitive function in patients with mild cognitive impairment: A retrospective analysis",
abstract = "Background and purpose: Cerebral ischemia and accumulation of amyloid β (Aβ) are major risk factors for the development of dementia, including vascular dementia and Alzheimer's disease. Cilostazol, an antiplatelet drug, has been shown to improve cerebral circulation and reduce accumulation of Aβ. In this study, the long-term effect of cilostazol on cognitive function was investigated retrospectively. Methods: Medical records at Sumotoitsuki Hospital were surveyed to find all patients treated with cilostazol and evaluated by the Mini-Mental State Examination (MMSE) during at least two visits separated by an interval of more than 6 months. Patients receiving anti-dementia drugs were excluded. Temporal changes in MMSE scores were compared between patients treated with cilostazol (n = 70) and those who ceased administration of this drug (n = 22). The mean follow-up period was 691 days. Results: Decrease in MMSE score was significantly ameliorated by administration of cilostazol. Subgroup analysis revealed that cilostazol significantly improved MMSE score in patients with mild cognitive impairment, though no significant effect was observed in patients with normal cognitive function or dementia. Conclusions: Although there are limitations to such a retrospective study, these results significantly encourage undertaking a prospective cohort study to determine the effect of cilostazol on mild cognitive impairment where no treatments currently exist.",
author = "Akihiko Taguchi and Yu Takata and Masafumi Ihara and Yukiko Kasahara and Masahiro Tsuji and Madoka Nishino and David Stern and Masahiro Okada",
year = "2013",
month = "9",
day = "1",
doi = "10.1111/psyg.12021",
language = "English (US)",
volume = "13",
pages = "164--169",
journal = "Psychogeriatrics",
issn = "1346-3500",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Cilostazol improves cognitive function in patients with mild cognitive impairment

T2 - A retrospective analysis

AU - Taguchi, Akihiko

AU - Takata, Yu

AU - Ihara, Masafumi

AU - Kasahara, Yukiko

AU - Tsuji, Masahiro

AU - Nishino, Madoka

AU - Stern, David

AU - Okada, Masahiro

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Background and purpose: Cerebral ischemia and accumulation of amyloid β (Aβ) are major risk factors for the development of dementia, including vascular dementia and Alzheimer's disease. Cilostazol, an antiplatelet drug, has been shown to improve cerebral circulation and reduce accumulation of Aβ. In this study, the long-term effect of cilostazol on cognitive function was investigated retrospectively. Methods: Medical records at Sumotoitsuki Hospital were surveyed to find all patients treated with cilostazol and evaluated by the Mini-Mental State Examination (MMSE) during at least two visits separated by an interval of more than 6 months. Patients receiving anti-dementia drugs were excluded. Temporal changes in MMSE scores were compared between patients treated with cilostazol (n = 70) and those who ceased administration of this drug (n = 22). The mean follow-up period was 691 days. Results: Decrease in MMSE score was significantly ameliorated by administration of cilostazol. Subgroup analysis revealed that cilostazol significantly improved MMSE score in patients with mild cognitive impairment, though no significant effect was observed in patients with normal cognitive function or dementia. Conclusions: Although there are limitations to such a retrospective study, these results significantly encourage undertaking a prospective cohort study to determine the effect of cilostazol on mild cognitive impairment where no treatments currently exist.

AB - Background and purpose: Cerebral ischemia and accumulation of amyloid β (Aβ) are major risk factors for the development of dementia, including vascular dementia and Alzheimer's disease. Cilostazol, an antiplatelet drug, has been shown to improve cerebral circulation and reduce accumulation of Aβ. In this study, the long-term effect of cilostazol on cognitive function was investigated retrospectively. Methods: Medical records at Sumotoitsuki Hospital were surveyed to find all patients treated with cilostazol and evaluated by the Mini-Mental State Examination (MMSE) during at least two visits separated by an interval of more than 6 months. Patients receiving anti-dementia drugs were excluded. Temporal changes in MMSE scores were compared between patients treated with cilostazol (n = 70) and those who ceased administration of this drug (n = 22). The mean follow-up period was 691 days. Results: Decrease in MMSE score was significantly ameliorated by administration of cilostazol. Subgroup analysis revealed that cilostazol significantly improved MMSE score in patients with mild cognitive impairment, though no significant effect was observed in patients with normal cognitive function or dementia. Conclusions: Although there are limitations to such a retrospective study, these results significantly encourage undertaking a prospective cohort study to determine the effect of cilostazol on mild cognitive impairment where no treatments currently exist.

UR - http://www.scopus.com/inward/record.url?scp=84884727142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884727142&partnerID=8YFLogxK

U2 - 10.1111/psyg.12021

DO - 10.1111/psyg.12021

M3 - Article

VL - 13

SP - 164

EP - 169

JO - Psychogeriatrics

JF - Psychogeriatrics

SN - 1346-3500

IS - 3

ER -